Endocrine Abstracts

Introduction: Immune-check point inhibitors (ICPis) has been shown to significantly improve survival in patients with advanced melanoma. Immune-related endocrinopathies (irEs) and in particular hypophysitis and thyroid dysfunction have been well described with an incidence varying from 9–17% and 3.8–13.2% respectively.Methods: This is a retrospective analysis of irEs in 325 (190 men) patients with melanoma receiving ICPis (PD-1/PDL-1 or CTLA-4 ...

Background: Immune checkpoint inhibitors (ICIs) constitutes a novel treatment for patients with melanoma. Endocrine-related adverse effects are now a distinctive clinical entity of ICIs, with hypophysitis and thyroiditis being the most common. Recent consensus doesn’t suggest routinely screening of bone mass indexes in patients on ICIs since data in the literature are scarce.Methods: Data regarding bone disease were retrospectively analysed in 118 p...

Background: Immune checkpoint inhibitors (ICIs) (anti-CTLA-4, PD-1 inhibitors, PD-L1 inhibitors) are considered a widely used therapeutic choice for several cancer types. However ICI therapy is frequently complicated by adverse events; endocrine toxicities are the most common ones.Methods: To assess in a retrospective observational study in a tertiary hospital the incidence and the characteristics of the immunotherapy-related endocrine adverse events (ir...

Context: Adrenal incidentalomas (AI) can be found in 3–10% of the general population. The vast majority of them (70%) represents nonfunctioning adrenal incidentalomas (NFAI). Although several comorbidities have been studied in patients with autonomous cortisol secretion (ACS) there are limited data for those with NFAI.Aim: To study metabolic disorders frequency in patients with AI and especially NFAI.Design: Retrospective stu...